Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
06 2019
Historique:
accepted: 27 10 2018
pubmed: 13 11 2018
medline: 22 8 2020
entrez: 13 11 2018
Statut: ppublish

Résumé

Data on dermatological manifestations of Noonan syndrome (NS) remain heterogeneous and are based on limited dermatological expertise. To describe the dermatological manifestations of NS, compare them with the literature findings, and test for dermatological phenotype-genotype correlations with or without the presence of PTPN11 mutations. We performed a large 4-year, prospective, multicentric, collaborative dermatological and genetic study. Overall, 129 patients with NS were enrolled, including 65 patients with PTPN11-NS, 34 patients with PTPN11-NS with multiple lentigines (NSML), and 30 patients with NS who had a mutation other than PTPN11. Easy bruising was the most frequent dermatological finding in PTPN11-NS, present in 53·8% of patients. Multiple lentigines and café-au-lait macules (n ≥ 3) were present in 94% and 80% of cases of NSML linked to specific mutations of PTPN11, respectively. Atypical forms of NSML could be associated with NS with RAF1 or NRAS mutations. In univariate analysis, patients without a PTPN11 mutation showed (i) a significantly higher frequency of keratinization disorders (P = 0·001), including keratosis pilaris (P = 0·005), ulerythema ophryogenes (P = 0·0001) and palmar and/or plantar hyperkeratosis (P = 0·06, trend association), and (ii) a significantly higher frequency of scarce scalp hair (P = 0·035) and scarce or absent eyelashes (P = 0·06, trend association) than those with PTPN11 mutations. The cutaneous phenotype of NS with a PTPN11 mutation is generally mild and nonspecific, whereas the absence of a PTPN11 mutation is associated with a high frequency of keratinization disorders and hair abnormalities.

Sections du résumé

BACKGROUND
Data on dermatological manifestations of Noonan syndrome (NS) remain heterogeneous and are based on limited dermatological expertise.
OBJECTIVES
To describe the dermatological manifestations of NS, compare them with the literature findings, and test for dermatological phenotype-genotype correlations with or without the presence of PTPN11 mutations.
METHODS
We performed a large 4-year, prospective, multicentric, collaborative dermatological and genetic study.
RESULTS
Overall, 129 patients with NS were enrolled, including 65 patients with PTPN11-NS, 34 patients with PTPN11-NS with multiple lentigines (NSML), and 30 patients with NS who had a mutation other than PTPN11. Easy bruising was the most frequent dermatological finding in PTPN11-NS, present in 53·8% of patients. Multiple lentigines and café-au-lait macules (n ≥ 3) were present in 94% and 80% of cases of NSML linked to specific mutations of PTPN11, respectively. Atypical forms of NSML could be associated with NS with RAF1 or NRAS mutations. In univariate analysis, patients without a PTPN11 mutation showed (i) a significantly higher frequency of keratinization disorders (P = 0·001), including keratosis pilaris (P = 0·005), ulerythema ophryogenes (P = 0·0001) and palmar and/or plantar hyperkeratosis (P = 0·06, trend association), and (ii) a significantly higher frequency of scarce scalp hair (P = 0·035) and scarce or absent eyelashes (P = 0·06, trend association) than those with PTPN11 mutations.
CONCLUSIONS
The cutaneous phenotype of NS with a PTPN11 mutation is generally mild and nonspecific, whereas the absence of a PTPN11 mutation is associated with a high frequency of keratinization disorders and hair abnormalities.

Identifiants

pubmed: 30417923
doi: 10.1111/bjd.17404
doi:

Substances chimiques

PTPN11 protein, human EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 11 EC 3.1.3.48

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1438-1448

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2018 British Association of Dermatologists.

Auteurs

D Bessis (D)

Department of Dermatology, Saint-Eloi Hospital, Competence Centre for Rare Skin Diseases, Montpellier, France.
University of Montpellier, Montpellier, France.
INSERM U1058, Montpellier, France.

J Miquel (J)

Department of Paediatric Dermatology, Femme-Mère-Enfant Hospital, University of South Réunion, Saint-Pierre Réunion, France.
Department of Dermatology, University of Rennes, Rennes, France.

E Bourrat (E)

Department of Paediatric Dermatology, Robert-Debré Hospital, AP-HP, Paris, France.

C Chiaverini (C)

Department of Dermatology, L'Archet 2 Hospital, Nice, France.
University of Nice, Nice, France.

F Morice-Picard (F)

Department of Paediatric Dermatology, Pellegrin University Hospital of Bordeaux, Bordeaux, France.

C Abadie (C)

Department of Clinical Genetics, Sud Hospital, Rennes, France.
University Hospital of Rennes, Rennes, France.

F Manna (F)

University of Montpellier, Montpellier, France.
Department of Medical Information, Epidemiological and Clinical Research Unit, La Colombière Hospital, Montpellier, France.

C Baumann (C)

Department of Clinical Genetics, Robert-Debré Hospital, AP-HP, Paris, France.
University of Paris-Diderot, Paris, France.

M Best (M)

Department of Dermatology, Saint-Eloi Hospital, Competence Centre for Rare Skin Diseases, Montpellier, France.
University of Montpellier, Montpellier, France.

P Blanchet (P)

Department of Clinical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France.

A-C Bursztejn (AC)

Department of Dermatology, Brabois Hospital, Nancy, France.
University of Nancy, Nancy, France.

Y Capri (Y)

Department of Clinical Genetics, Robert-Debré Hospital, AP-HP, Paris, France.
University of Paris-Diderot, Paris, France.

C Coubes (C)

Department of Clinical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France.

F Giuliano (F)

University of Nice, Nice, France.
Department of Clinical Genetics, L'Archet 2 Hospital, Nice, France.

S Guillaumont (S)

University of Montpellier, Montpellier, France.
Department of Paediatric Cardiology, Arnaud de Villeneuve Hospital, Montpellier, France.

S Hadj-Rabia (S)

Department of Paediatric Dermatology, Reference Centre for Rare Skin Diseases, Necker-Enfants Malades Hospital, AP-HP, Paris, France.

M-L Jacquemont (ML)

Department of Clinical Genetics, Femme-Mère-Enfant Hospital, University of South Réunion, Saint-Pierre Réunion, France.

C Jeandel (C)

University of Montpellier, Montpellier, France.
Department of Paediatric Endocrinology, Arnaud de Villeneuve Hospital, Montpellier, France.

D Lacombe (D)

Department of Clinical Genetics, Pellegrin University Hospital of Bordeaux, AP-HP, Paris, France.

S Mallet (S)

Department of Dermatology, La Timone Hospital, AP-HM, Marseille, France.
University of Marseille, Marseille, France.

J Mazereeuw-Hautier (J)

Department of Dermatology, Larrey Hospital, Reference Centre for Rare Skin Diseases, Toulouse, France.
University of Toulouse, Toulouse, France.

N Molinari (N)

University of Montpellier, Montpellier, France.
Department of Medical Information, Epidemiological and Clinical Research Unit, La Colombière Hospital, Montpellier, France.

V Pallure (V)

Department of Dermatology, CH, Perpignan, Perpignan, France.

C Pernet (C)

Department of Dermatology, Saint-Eloi Hospital, Competence Centre for Rare Skin Diseases, Montpellier, France.

N Philip (N)

University of Marseille, Marseille, France.
Department of Clinical Genetics, La Timone Hospital, AP-HM, Marseille, France.

L Pinson (L)

Department of Clinical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France.

P Sarda (P)

Department of Clinical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France.

S Sigaudy (S)

University of Marseille, Marseille, France.
Department of Clinical Genetics, La Timone Hospital, AP-HM, Marseille, France.

Y Vial (Y)

University of Paris-Diderot, Paris, France.
Department of Genetic Biochemistry, Robert-Debré Hospital, AP-HP, Paris, France.

M Willems (M)

Department of Clinical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France.

D Geneviève (D)

Department of Clinical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France.
INSERM U1183, Montpellier, France.

A Verloes (A)

Department of Clinical Genetics, Robert-Debré Hospital, AP-HP, Paris, France.
University of Paris-Diderot, Paris, France.

H Cavé (H)

University of Paris-Diderot, Paris, France.
Department of Genetic Biochemistry, Robert-Debré Hospital, AP-HP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH